Evoke Pharma (NASDAQ:EVOK) Share Price Passes Below Two Hundred Day Moving Average – Should You Sell?

Evoke Pharma, Inc. (NASDAQ:EVOKGet Free Report) shares passed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $3.69 and traded as low as $2.66. Evoke Pharma shares last traded at $2.76, with a volume of 5,680 shares trading hands.

Wall Street Analyst Weigh In

Separately, Wall Street Zen initiated coverage on shares of Evoke Pharma in a report on Thursday, May 15th. They issued a “sell” rating for the company.

Get Our Latest Stock Report on EVOK

Evoke Pharma Stock Down 0.2%

The company’s 50-day moving average is $3.02 and its two-hundred day moving average is $3.69. The company has a market capitalization of $4.10 million, a P/E ratio of -0.96 and a beta of 0.04.

Evoke Pharma (NASDAQ:EVOKGet Free Report) last issued its quarterly earnings results on Monday, May 12th. The specialty pharmaceutical company reported ($0.51) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.18). Evoke Pharma had a negative net margin of 43.80% and a negative return on equity of 101.91%. The business had revenue of $3.08 million for the quarter, compared to the consensus estimate of $3.32 million.

Hedge Funds Weigh In On Evoke Pharma

An institutional investor recently raised its position in Evoke Pharma stock. Nantahala Capital Management LLC boosted its holdings in shares of Evoke Pharma, Inc. (NASDAQ:EVOKFree Report) by 163.5% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 148,194 shares of the specialty pharmaceutical company’s stock after purchasing an additional 91,945 shares during the period. Nantahala Capital Management LLC owned about 9.95% of Evoke Pharma worth $655,000 at the end of the most recent reporting period.

Evoke Pharma Company Profile

(Get Free Report)

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.

See Also

Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.